Clinical Trial Goal
To find out:
- The highest dose of ropeginterferon alfa-2b that's safe to give
- If ropeginterferon alfa-2b is safe and works well to treat CTCL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have CTCL, stage 1A - 3B, that has relapsed or is refractory
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Ropeginterferon alfa-2b is a pegylated interferon, that binds to interferon receptors and helps the body fight cancer and infections.
You'll get:
You'll get:
- Ropeginterferon alfa-2b – Given as a shot under your skin 1 time every 2 weeks
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved ropeginterferon alpha-2b to treat polycythemia vera. Using it in this way to treat CTCL that has relapsed or is refractory is new and unproven.
Locations
Moffitt Cancer CenterRECRUITING
Tampa, Florida
Sponsors
collaborator: PharmaEssentia, lead: H. Lee Moffitt Cancer Center and Research Institute
